ROYALTY PHARMA OA DL-0001

Royalty Pharma’s stock rose to a new record high of $62.48 and is currently trading at $62.58, implying a market capitalization of $35.87 billion. Year to date the shares are up 69.78%. For Q2 2026 the company reported licensing revenue of $768 million (+14% year over year) and portfolio revenue of $773 million (+6%), after which BofA raised its price target from $62.00 to $63.00 and kept its rating at "Buy." However, an analysis by InvestingPro classifies the stock as overvalued relative to its fair value. » More on de.investing.com

Royalty Pharma’s stock rose to a record high of $60.44 and is trading near its 52-week high after gaining 69% last year. For Q2 2026 the company reported royalties of $768 million (+14%) and portfolio revenues of $773 million (+6%), after which the full-year guidance was raised for the second time. BofA raised its price target to $63.00 and reiterated a “buy” rating, citing strong sales of products such as Tremfya, Voranigo, Imdelltra and Evrysdi. » More on de.investing.com

Royalty Pharma has declared a dividend of US$0.235 per Class A common share for the third quarter of 2026. The payment will be made on 10 September 2026 to shareholders of record at the close of trading on 14 August 2026. The current dividend yield is 1.61%; the company has raised the dividend for six consecutive years. Royalty Pharma invests in biopharmaceutical royalties and recorded a 69% share price increase last year, trading near its 52‑week high of US$58.84. » More on de.investing.com